Skip to main content

Building

A better future

through education, skill development and research

LEARN MORE

Antihormone Therapy Linked with Higher Heart Failure Risk in Prostate Cancer Patients

Androgen deprivation therapy was associated with a 72 percent higher risk of heart failure in a study of patients with prostate cancer.

Wednesday, November 7, 2018 12:01 am EST
"We recommend that clinicians should counsel their patients regarding modifiable heart failure risk factors, suggest they improve their lifestyle, and further provide relevant cardiovascular examination for prostate cancer patients receiving androgen deprivation therapy."

Androgen deprivation therapy was associated with a 72 percent higher risk of heart failure in a study of patients with prostate cancer. 

In The Journal of Clinical Pharmacology study, incidence rates of heart failure per 100 person-years within a 1-year follow-up period were 4.00 and 1.89 for androgen deprivation therapy users and nonusers, respectively. (A person-year is the number of years of follow-up multiplied by the number of people in the study.) The study included data from the Taiwan Longitudinal Health Insurance Database 2005 on 1244 patient who received androgen deprivation therapy and 1806 patients who did not.

 “The results of our study provide information for prostate cancer patients to be aware of the potential heart failure risk of receiving androgen deprivation therapy,” the authors wrote. “We recommend that clinicians should counsel their patients regarding modifiable heart failure risk factors, suggest they improve their lifestyle, and further provide relevant cardiovascular examination for prostate cancer patients receiving androgen deprivation therapy.”

Additional Information

Link to Study: https://onlinelibrary.wiley.com/doi/full/10.1002/jcph.1332

About Journal

The Journal of Clinical Pharmacology (JCP) is a Human Pharmacology journal designed to provide physicians, pharmacists, research scientists, regulatory scientists, drug developers and academic colleagues a forum to present research in all aspects of Clinical Pharmacology. This includes original research in pharmacokinetics, pharmacogenetics/pharmacogenomics, pharmacometrics, physiologic based pharmacokinetic modeling, drug interactions, therapeutic drug monitoring, regulatory sciences (including unique methods of data analysis), special population studies, drug development, pharmacovigilance, womens’ health, pediatric pharmacology, and pharmacodynamics. Additionally, JCP publishes review articles, commentaries and educational manuscripts. The Journal also serves as an instrument to disseminate Public Policy statements from the American College of Clinical Pharmacology.

The journal is a member of the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors (ICMJE).

About Wiley

Wiley is a global leader in research and education. Our online scientific, technical, medical, and scholarly journals, and our digital learning, assessment, certification and student-lifecycle services and solutions help universities, academic societies, businesses, governments and individuals to achieve their academic and professional goals. For more than 200 years, we have delivered consistent performance to our stakeholders. The Company's website can be accessed at www.wiley.com.

Multimedia Files:

Preview image

Contact:

Penny Smith
+44 (0) 1243 770448
newsroom@wiley.com

Business Wire NewsHQsm